Cancer Nanotechnology

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Biomaterials for Immunity and Cancer
Room: 210/211

About

The cellular and therapeutic aspects of nanotechnology as it applies to the cancer will be covered under this session. The session would solicit abstracts from the biomaterial community working on the application of nano-biomaterial technologies to cancer. Nanomaterials used for the detection and treatment of cancer affect the translation of nanotechnology for cancer therapy. The field of nanotechnology translates clinically into the field of nanomedicine. Thus, the field of nanomedicine is affected by upcoming nanotechnologies although may not be directly covered by this session. Cancer detection at the nanoscale requires nanotechnologies such as quantum dots and these types of technologies are covered by this session. The cellular and extracellular make-up of cancer and its milieu detection, characterization, and treatment as linked to nanotechnologies are applicable areas for this session.

Abstracts

  • 1:00 p.m. 40. Disrupting Physical Interactions Between Multiple Myeloma and the Bone Marrow Niche via Nanoparticle-Mediated RNAiDisrupting Physical Interactions Between Multiple Myeloma and the Bone Marrow Niche via Nanoparticle-Mediated RNAi, M Mitchell*(1), R Langer(2); (1)University of Pennsylvania, Philadelphia, PA, (2)MIT, Cambridge, MA

  • 1:15 p.m. 41. Targeted combinatorial drug delivery using stimuli-responsive mesoporous silica nanoparticles for pancreatic ductal adenocarcinoma therapy, M Tarannum*, J Vivero-Escoto; University of North Carolina at Charlotte, Charlotte, NC

  • 1:30 p.m. 42. Targeted anti-angiogenesis therapy for cancer treatment, Y Li*, C Mao; University of Oklahoma, Norman, OK

  • 1:45 p.m. 43. T Cell-Engaging Self-Assembled Bispecific Antibody Nanoparticles Against Breast Cancer Cells, W Lv*, J Champion; Georgia Institute of Technology, Atlanta, GA

  • 2:00 p.m. 44. Nanoparticles Coated with Frizzled7 Antibodies Enable Multivalent Binding for Enhanced Wnt Signaling Inhibition in Triple-Negative Breast Cancer, R. Riley, E. Day*; University of Delaware, Newark, DE

  • 2:15 p.m. 45. Using Nucleic Acids to Target Nanoparticles to Drug-Eluting Gels for Local Drug Release, Y. Brudno*(1), E. Silva(2), C. Kearney(3), M. Aizenberg(4), D. Mooney(5); (1)North Carolina State University, Raleigh, NC, (2)UC Davis, Davis, CA, (3)Royal College of Surgeons in Ireland, Dublin, Ireland, (4)Wyss Institute, Harvard University, Cambridge,

  • 2:30 p.m. 46. Nano-Bio Interactions to Enhance the Systemic Circulation Time and Tumor Targeting Efficiency of Nanomedicine in Cancer, S. Kesharwani*(1), P. Muley(1), A. Ukidve(2), G. Bhat(1), S. Mitragotri(2), H. Tummala(1); (1)South Dakota State University, Brookings, SD, (2)Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA

  • 2:45 p.m. 47. TRAIL-coated Leukocytes to Kill Tumor Cells in the Blood of Prostate Cancer Patients, N. Ortiz Otero*(1), J. Marshall(2), E.M Messing(3), D.M. Sahasrabudhe(3), M.R. King(1); (1)Vanderbilt University, Nashville, TN, (2)Cornell University, Ithaca, NY , (3) University of Rochester Medical Center, Rochester, NY